Remicade Patent Protection
0 patents · Janssen Biotech Inc.
Biosimilar Pathway
Remicade (infliximab) is a biologic, not a small-molecule drug. Biologics are not listed in the FDA Orange Book and do not face conventional “generic” competition. Instead, follow-on competitors called biosimilars can be approved through the FDA’s BPCIA pathway, typically after the reference product’s 12-year exclusivity period and the resolution of any patent litigation.
For the current biosimilar approvals and exclusivity status of Remicade, see the authoritative FDA Purple Book listing for infliximab.
Related Drug Patent Expirations
0 patents · Janssen Biotech Inc.
0 patents · Janssen Biotech Inc.
0 patents · Janssen Biotech Inc.
0 patents · Genentech Inc.
9 patents · earliest expires 2033 · Gilead Sciences Inc.
0 patents · Novartis AG
The Remicade record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how Remicade sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Remicade’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.